EP1204761B1 - Gezielte verabreichung von kuenstlichen genen - Google Patents

Gezielte verabreichung von kuenstlichen genen Download PDF

Info

Publication number
EP1204761B1
EP1204761B1 EP00957535A EP00957535A EP1204761B1 EP 1204761 B1 EP1204761 B1 EP 1204761B1 EP 00957535 A EP00957535 A EP 00957535A EP 00957535 A EP00957535 A EP 00957535A EP 1204761 B1 EP1204761 B1 EP 1204761B1
Authority
EP
European Patent Office
Prior art keywords
vector
viral
cell
targeting
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00957535A
Other languages
English (en)
French (fr)
Other versions
EP1204761A2 (de
Inventor
Yanina Rozenberg
Viacheslav Medvedkin
W. French Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of EP1204761A2 publication Critical patent/EP1204761A2/de
Application granted granted Critical
Publication of EP1204761B1 publication Critical patent/EP1204761B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Definitions

  • the invention provides improved vectors for cell-specific gene delivery to a target cell.
  • the vectors according to the instant invention comprise a recombinant core containing the genetic materials to be delivered and an artificially reconstituted surface encompassing the core.
  • the surface facilitates targeting and cell fusion of the vector, and also provides an immunoprotection function for the vector.
  • Methods for preparing the vectors and for transfecting eukaryotic cells using the vectors also are disclosed.
  • Gene therapy has received a great deal of attention for its potential of providing effective treatment of many human diseases, ranging from rare heritable genetic defects and common diseases such as cancer, AIDS, hypertension, atheroma and diabetes.
  • the great potential of gene therapy has up until now been hampered by the lack of efficient vector systems for delivery of genetic constructs into cells in vivo and ex vivo.
  • an ideal gene delivery vector should possess several attributes.
  • the vector should be able to reach a target site within the organism, and preferably should be able to recognize the specific cell types. This requires that the vector have low immunogenicity as well as targeting characteristics.
  • the vector should be able to cross the membrane barrier of host cells to deliver its therapeutic genetic material into the inside of the cells. The capacity of the current vector systems is in most cases large enough to accommodate the delivery of the desired genetic constructs.
  • the expression preferably is cell-specific, and is non-harmful overall. In most applications the vector should lack the ability to autonomously replicate its own DNA. Fourth, where necessary, the vector should provide controlled, sustained gene expression over an extended time period. Fifth, the vector should be amenable to manufacture on a commercial scale, and be available in a pharmaceutically deliverable, concentrated form.
  • viral delivery systems and cationic polymer or lipid-based systems.
  • viral based systems the natural cell penetration ability of the viruses is retained in the genetically modified viruses manipulated to deliver therapeutic genes.
  • polymer or lipid-based systems therapeutic DNA is condensed with one or more cationic polymers and/or cationic lipids, and cellular delivery exploits the attraction between the negatively charged cell and positively charged gene delivery particle. In the majority of current applications, the targeting of specific cell types has not been achieved.
  • Viral vectors as a class suffer several significant failings, such as the inability to efficiently escape the host immune system, restrictions on the types of cell that can be infected, difficulties in producing vectors with high titers, limits on the ability to package large DNA or RNA molecules, and integration into the host genome, which is advantageous for stable expression, yet produces a finite, albeit low, chance of an undesirable insertion into a functional genomic site.
  • Gene transfer using nucleic acids encapsulated into agents such as polymers or lipids has the ability to transfect a broad spectrum of host cells in vitro , but also suffers from problems for in vivo delivery such as inability to evade the immune system, lack of cell specificity, low efficiency of cell entry due to the lack of entry mechanisms, and low efficiency of vector unpackaging once within a cell.
  • the combination of viral and non-viral elements can be used to increase the efficiency of gene transfer to cells.
  • Fasbender et al. J. Biol. Chem. 272:6479-6489 (1997) ) described the incorporation of adenoviral lysosomal degradation escape functions into an artificially packaged DNA formulation in order to enhance the delivery efficiency of the encapsulated DNA.
  • Another example of a combination of viral and non-viral elements uses plasmids containing the inverted terminal repeat (ITR) sequences of adeno associated virus (AAV) complexed to cationic liposomes, where gene transfer and subsequent interleukin-2 (IL-2) gene expression was 3-10 times higher than the levels obtained with plasmids lacking the ITRs.
  • ITR inverted terminal repeat
  • AAV adeno associated virus
  • adenoviral capsid proteins or adenoviral fiber proteins were combined with liposomes, providing an increased transfection efficiency of a reporter gene. Hong et al., Chinese Medical J. 108:332-337 (1995) .
  • a non-naturally occurring gene therapy vector comprising a recombinant core and a non-naturally occurring functional surface moiety, where the said core comprises a nucleic acid molecule, and where at least one expression product of the vector is a therapeutic nucleic acid, peptide or protein, where the functional surface moiety comprises an immuno-protective element, a targeting element, and a cell-entry element, and where the vehicle is capable of specifically binding to and delivering the core into a target cell.
  • the core further comprises at least one viral capsid protein.
  • the functional surface moiety comprises an immunoprotective element, a targeting element, and a cell-entry element.
  • the immunoprotective element comprises a synthetic polymer moiety.
  • the synthetic polymer component may comprise a poly(ethyleneglycol).
  • the synthetic polymer component comprises a copolymer of glutamic acid with leucine.
  • the targeting moiety binds to a receptor that is more highly expressed in diseased cells than in normal cells.
  • the targeting moiety is a peptide ligand for a cell surface receptor.
  • the cell-entry element is a membrane-destabilizing moiety comprising an amphiphilic ⁇ -helix.
  • the amphiphilic ⁇ -helix may be derived from the C-terminal domain of a viral env protein.
  • that C-terminal domain is the C-terminal domain of the Moloney leukemia virus env protein.
  • That C-terminal domain may comprise amino acids 598-616 of the Moloney leukemia virus env protein.
  • the membrane-destabilizing moiety comprises a copolymer of glutamic acid with leucine.
  • the functional surface contains molecular elements that enable the vector to evade the host's immune system, to recognize and bind to specific target cells, and to efficiently fuse with the target cell and deliver a transgene encoded by the core gene complex into the target.
  • the surface molecular elements can contain, for example, multiple peptides and immunoprotective elements.
  • the invention provides vectors where an existing lipid envelope moiety of a recombinant virus is modified to enhance or provide the desired characteristics of the viral particle.
  • a viral surface can be manipulated to add immunoprotective elements, for example polymer groups such as poly(ethyleneglycol) (PEG), which decrease the immunogenicity of the viral particle, and also increase the stability of the vector in blood circulation.
  • the surface also can be modified by addition of targeting ligands that enhance the cell specificity of the virus.
  • the surface can be engineered to include a ligand molecule that can specifically interact with a receptor of choice on the surface of a target cell.
  • the surface is modified to include elements that enhance the cell entry properties of the vector.
  • fusogenic peptides, proteins, or polymers may be used to enhance entry of the vector into the target cell.
  • a fusogenic moiety promotes fusion of the vector to the cell membrane of the target cell, facilitating entry of the viral core into the cell cytoplasm.
  • the fusogenic moiety may be a naturally occurring fusogen, such as a viral fusogenic peptide, or may be an engineered (non-naturally occurring) moiety, such as a peptide containing a membrane-active amphiphilic ⁇ -helix or some other conformational feature that provides membrane destabilization.
  • the fusogenic moiety can be a polymer that provides membrane destabilization.
  • modifications to the existing surface of a gene delivery particle can be made non-covalently, where lipids modified by chemical conjugation to contain functional moieties are incorporated into the surface of the core containing particle. This incorporation is done, for example, by forming micelles containing the desired modifying moiety, where the micelles are spontaneously fused to the surface of a particle using methods that are known in the art. Non-covalent modifications also can be made by adsorbing functional components onto the the surface of a particle by electrostatic and/or hydrophobic (van der Waals) interactions.
  • the modifications can be made by covalent modification of the constituents of the surface of a gene delivery particle.
  • the membrane lipids on the viral surface can be linked to chemically activated linkers to allow subsequent covalent attachment of modifying groups.
  • the carbohydrate groups on membrane glycoproteins can be chemically oxidized using methods that are well known in the art to produce reactive aldehyde groups, which permit covalent modification with, for example, polymeric materials or peptides containing free amino groups.
  • Other methods of covalent modification of membrane constituents are well known in the art.
  • an existing viral surface can be chemically modified at the lipid and/or protein components by reaction with activated compounds.
  • Activated linker compounds include, but are not limited to, the incorporation of highly reactive chemical groups, for example: sulfonyl halides and/or various active esters of carboxylic acids for the modification of amino groups; hydrazides for modification of carbohydrates; maleimidoyl or reactive alkylhalides for modification of thiol groups; and photoactivated groups that are known in the art. The skilled artisan will be aware that the use of other chemically activated groups is also possible.
  • functional groups on the surface of a gene delivery particle can be chemically modified using methods known in the art to produce reactive and/or chemically selective groups, which permit covalent modification with, for example, polymeric materials or peptides containing free amino groups.
  • a specific example is modification of the viral surface with 2-iminothiolane (Traut's reagent), which converts accessible amino groups on the viral surface into sulfhydryl groups. This allows for enhanced selectivity of modification by using thiol-selective methods of conjugation. Modification of the viral surface with Traut's reagent also provides a very convenient means for estimating the optimal effective level of the chemical modification of various viruses.
  • the functional group that is to be introduced into the vector is first conjugated to an activated linker.
  • This linker preferably possesses hydrophobic loci for better affinity to the surface of the gene delivery particle.
  • a copolymer of glutamic acid and leucine (described in more detail below) maybe used.
  • the linker also may carry a positive charge for better affinity to the cell surface.
  • Some proportion of the active groups can be retained (or created de novo) for the covalent attachment of the linker to the surface of a particle.
  • this linker can be used to modify the surface of viruses in multiple ways without exposing fragile viruses to excessive chemical treatment.
  • Figure 1 shows a schematic diagram for a surface of TAGD particle containing an immunoprotective element (PEG), a fusogenic element (the membrane destabilizing peptide) and a cell binding element (the targeting peptide).
  • Figure 2 shows two different methods by which ligands can be incorporated into the viral surface.
  • vectors are provided where the vector contains a recombinant core within a surface that is prepared de novo.
  • This embodiment is suitable for use with viral core particles whether or not the particle contains an existing membrane.
  • a recombinant viral particle that lacks an outer membrane layer can be encased within an artificially generated lipid membrane.
  • a recombinant viral particle that contains an outer membrane layer can be modified (i) by chemical methods, (ii) by encapsulation within a new membrane, or (iii) by replacement of the existing membrane, to contain new surface elements synthesized de novo.
  • the surface of the resulting particles can be engineered to contain immunoprotective, fusogenic, and cell-specificity enhancing agents as described above.
  • the membrane can contain components that enhance the stability of the vector in the circulation of the host, thereby improving the chance that the vector will reach its intended target, and also providing an opportunity for increased duration of action of the vector.
  • the viral core is the viral core
  • the viral core moiety of the vector may be any recombinant viral core that is suitable for use in gene therapy.
  • suitable viral cores can be prepared by methods that are well known in the art and can be used as the internal components of the TAGD vehicles.
  • viruses used in gene therapy see Jain, "Textbook of Gene Therapy", Chapter 4, pp. 35-66 (Hogrefe &Huber, 1998 ).
  • Suitable viral cores include recombinant viruses, for example, replication-defective lentivirus, such as HIV, or other retroviruses, for example, murine leukemia viruses (MLV) such as Moloney murine leukemia virus (MoMLV) or Friend MLV, adenovirus, adeno-associated virus (AAV), herpes simplex type 1 (HSV-1), vaccinia virus, Epstein-Barr virus, rabies and pseudorabies virus, Sindbis virus, SV40, and cytomegalovirus, influenza virus, baculovirus, Semliki Forest Virus(SFV), and vesicular Stomatitis virus (VSV), etc.
  • MMV murine leukemia viruses
  • MoMLV Moloney murine leukemia virus
  • AAV adeno-associated virus
  • HSV-1 herpes simplex type 1
  • vaccinia virus Epstein-Barr virus
  • rabies and pseudorabies virus Sindbis virus
  • viruses may be engineered so as to lack a functional env gene if necessary. Removal of the env gene by recombinant methods reduces the immunogenicity of the virus, and also may increase the production levels of virions in cell culture. Viruses in which the env gene has been removed lack a natural ability to bind and fuse to target cells. Accordingly, these abilities must be provided by the TAGD vector.
  • compositions described herein are also suitable for use with viral core analog (nucleic acid) cores that may be developed in the future.
  • an immunoprotective element is a molecule or collection of molecules that are disposed on the surface of the vectors and thereby reduce the immunogenicity of the vector. That is, when the vector is administered to a patient, the element reduces the interaction of the vector with the components of the patient's serum, thus avoiding activation of the immune system, and lowering the in vivo clearance rate of the vector in the patient.
  • immunoprotective strategies include decreasing the charge of a drug delivery particle and/or its molecular mass, and decreasing the particle's hydrophilicity by glycosylation.
  • the most widely used approach is to attach "immuno-decoy" elements to the surface of a particle that reduce recognition of the particles by the opsonins in blood serum, thereby delaying or avoiding entirely activation of the immune system.
  • One method of attaching decoy polymers to a drug delivery vehicle is via polymer conjugation to lipids.
  • the polymer most commonly for this purpose used is poly(ethylene glycol) (PEG) ( Papahadjopoulos et al., Proc Natl Acad Sci USA. 15:11460-4 (1991 ).
  • sialic acid GM1 polyglycerols Schauer, TIBS Sept. 1985:357 , Yamanauchi et al., J. Controlled Release 113:141(1995 ): polyoxazoline-DSPE (distearoylphosphatidylethanolamine) derivatives ( Zalipsky et al., J Pharm Sci. 85:133-7 (1996 )), polymer-based 'stealth' approaches ( Torchilin et al., J Pharm Sci. 84:1049 (1995 )), phosphatidylpolyglycerol ( Maruyama et al., Biochim Biophys Acta.
  • fleximer polymers (( Papisov. Adv. Drug Delivery Review 32, 119-138 (1998 ); Torchilin J. Microencapsulation 15, 1-19 (1998) ).
  • Alternative immunoprotective elements include, but are not limited to, polyglutamic acid, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, polymethacrylamide, polyethyloxazoline, polymethyloxazoline, and polyvinylalcohol. As described above for PEG, each of these hydrophilic polymers can, if necessary, be covalently coupled to the vector through a reactive chemical group.
  • the present invention also provides a novel combinatorial linker based on copolymers of glutamic acid with leucine that can be used to introduce desired function to the surface of a particle and that has immunoprotective function.
  • glutamic acid contains a hydrophilic carboxyl side chain, where as leucine contains a hydrophobic side chain.
  • Each of these components can be substituted with other components that share functional characteristics.
  • glutamic acid can be substituted by, for example, aspartic acid
  • leucine can be substituted by, for example, alanine, phenylalanine, isoleucine, valine and other hydrophobic amino acids. Natural or non-natural amino acids may be used.
  • the hydrophobic function can be introduced as an ester or amide derivative of glutamic acid.
  • random copolymers and/or block copolymers may be used for the analogous purposes.
  • the PEG When PEG is used as the immunoprotective element, the PEG preferably has a molecular weight of between about 1,000 to about 5,000 daltons. Advantageously, PEG having a molecular weight of about 2000 daltons is used to achieve the immunoprotection.
  • PEG chain containing a reactive functional group on the surface of the membrane-containing drug delivery vector PEG may be conjugated to a phospholipid such as desteroyl phosphatidylethenolamine (DSPE).
  • DSPE desteroyl phosphatidylethenolamine
  • Suitable DSPE-PEG molecules that contain further modifiable PEG are well known in the art and also can be purchased from, for example, Shearwater Polymers (Huntsville, AL).
  • incorporation of an immunoprotective element into a surface of a gene delivery vector can be carried out via micelle formation.
  • a gene delivery vector such as a viral core surrounded by a membrane
  • micelle formation See, for example, Uster et al., Febs Lett. 386:243 (1996 ).
  • Molecules of DSPE-PEG are amphiphilic and spontaneously form micelles that are thermodynamically unstable and fuse with larger membrane surfaces of the virions. Successful insertion in this manner can be verified using the methods described below.
  • the effect of incorporation of immunoprotective elements on the blood clearance rate of particles also can be monitored using isotope-labeled particles.
  • the present invention provides a novel multivalent and multifunctional linker, based on activated copolymers of acidic and hydrophobic amino acids, like glutamic acid and leucine, and functional equivalents thereof, as detailed below.
  • Activation of such a linker can be performed by reacting the polymer with di-pentafluorophenylcarbonate in the presence of a tertiary amine.
  • the skilled artisan will be aware that the use of other alternative means of activation such as N, N-dicyclohexylcarbodiimide-hydroxysuccenemide, BOP-reagent, and the use of other condensing reagents known in peptide chemistry is possible.
  • Desired functional groups such as PEG or targeting or fusogenic peptides may then be conjugated to the activated linker.
  • This linker possesses hydrophobic loci for better affinity to the viral membrane, and also retains some positive charges for better affinity to the cell surface. Some proportion of the active groups can be retained (or created de novo) for the covalent attachment of the linker to the carrier.
  • This linker may be used to modify the surface of viruses in multiple ways without exposing fragile viruses to excessive chemical treatment.
  • a targeting element potentiates highly specific attachment of the vector to the target cell membrane.
  • a targeting element may be a targeting polypeptide containing a binding region that binds to a receptor or ligand on the surface of the target cell.
  • a targeting element may be selected from the group consisting of an antibody or a fragment thereof, a receptor ligand, a complete protein, a peptide, a receptor, a non-peptidic organic molecule that serves as a ligand, a vitamin, and an inorganic co-factor for a cell-surface protein.
  • the targeting element may bind to a receptor that is more highly expressed in the desired host cells targeted for genetic therapy, for example, the cancer cells.
  • Suitable ligands include, but are not limited to, vascular endothelial cell growth factor, for targeting endothelial cells, FGF2, for targeting blood vessels, and laminin and RGD peptides, for targeting integrin expressing cells.
  • Other examples include (i) folate, where the composition is intended for treating tumor cells having cell-surface folate receptors, (ii) pyridoxyl, where the composition is intended for treating virus-infected CD4 + lymphocytes, or (iii) sialyl-Lewis ox , where the composition is intended for treating a region of inflammation.
  • the targeting moiety can be a peptidomimetic.
  • the peptidomimetic can be directed at a receptor or other target on cancer cells.
  • a peptidomimetic analog of ⁇ -Melanostatin, ([Nle4, D-Phe7]- ⁇ -MSH) can be used for treatment of melanoma, where melanoma cells overexpress the - ⁇ -MSH receptor.
  • Other cancer-related peptidomimetics are known in the art. See, for example Kieber-Emmons et al, 1997 supra; Haubner et al, supra. Neurotensin, and the receptor-binding site of plasminogen activator also have been described as cancer-related ligands ( Schnierle and Groner, Gene Ther. 3:1069-73 (1996 )).
  • Other targeting ligands are described in US Patent No. 5,916,803 .
  • suitable peptide ligands can be selected using phage display methods that are well known in the art. Suitable methods are described, for example, in US Patent No. 5,780,221 . Briefly, libraries of short nucleic acid sequences encoding peptides of random sequence and pre-selected length are fused in-frame to genes encoding surface proteins of filamentous phage, and the resulting peptides are expressed (displayed) on the surface of the phage. The phage are then screened for the ability to bind, under appropriate conditions, to a target molecule, such as a cell surface receptor, immobilized on a solid support.
  • a target molecule such as a cell surface receptor
  • phage libraries Large libraries of phage can be used, allowing simultaneous screening of the binding properties of a large number of peptide sequences. Phages that have desirable binding properties are isolated and the sequences of the nucleic acids encoding the corresponding peptide ligands are determined. These peptides can be used as ligands directly in the methods of the present invention, or can be used as templates for the design and synthesis of peptidomimetics that are used as the targeting element.
  • the number of targeting moieties present on the TAGD vector surface will vary, depending on factors such as the avidity of the ligand-receptor interaction, the relative abundance of the receptor on the target cell surface, and the relative abundance of the target cell. Nevertheless, it is anticipated that at least 20-100 targeting molecules must be present on the surface of each vector to provide suitable enhancement of cell targeting.
  • the targeting moiety may be incorporated into the TAGD vector surface using a variety of methods, for example, via a thermodynamically unstable micellar intermediate, as described in more detail below.
  • the targeting moiety can be added using a polylinker in the same manner as described above for addition of PEG to the vector surface.
  • the targeting moiety can be coupled to the surface by standard linker chemistry. See for example, Hermanson, Bioconjugate Techniques(Pierce Chemical Company/Academic Press, San Diego, p785 (1996 )).
  • the targeting moiety can be chemically coupled to the lipid-polymer conjugate via a "donor-acceptor" type of reaction.
  • the targeting moiety can be designed to carry a free sulfhydryl group (donor) that can react with a maleimido group (acceptor) present on the lipid-conjugated polymer. Progress of this reaction can be monitored by observing the reduction in UV absorption at 300 nm due to loss of the maleimide chromophore, and loss of free sulfhydryl, measured using Ellman's reagent.
  • nucleophilic amine group with an activated carboxyl group, such as an N-hydroxysuccinimidyl ester (acceptor).
  • acceptor an activated carboxyl group
  • the donor moiety may be present on the particle surface, and the acceptor on the targeting moiety, or vice versa, as necessary.
  • the targeting moiety also can be coupled directly to the lipid membrane of the TAGD vehicle, to a lipid-polymer conjugate component of the vector, or to any other suitable disposed surface moiety present on the vector.
  • the targeting moiety retains the ability to bind its intended target.
  • This can be done using methods that are known in the art.
  • the ability of the non-conjugated targeting moiety to bind to its cognate receptor can be compared to the binding ability of the coupled moiety. This comparison can be done using the assembled TAGD vector, but is more conveniently achieved by comparing the coupled and non-coupled moieties prior to incorporation into the TAGD vector.
  • the comparison may be achieved by carrying out a model reaction where the targeting moiety is coupled to the vector component or components, and the resulting model compound then is compared with the non-conjugated targeting moiety.
  • ⁇ -MSH melanostatin
  • ⁇ -MSH can be synthesized with a maleimido function that can be conjugated to a DSPE conjugate of PEG that contains a sulfhydryl group (SH).
  • SH sulfhydryl group
  • the ⁇ -MSH, DSPE-PEG-SH, and DSPE-PEG- ⁇ -MSH conjugates can be compared at the same nanomolar concentrations for their ability to induce melanin formation in melanoma B16 cells. It is found that the conjugated peptide has similar activity to the non-conjugated ⁇ -MSH peptide.
  • incorporation of the conjugates into the TAGD vector can be achieved using the ability of micelles to fuse with larger membrane surfaces. Suitable methods are described in Kirpotin et al. (FEBS Lett. 388:115-8, (1996) ). See also Uster, supra.
  • a lipid-PEG- 125 I ⁇ -MSH conjugate may be incubated with MoMuLV viral particles. The resulting virions are purified first by step sucrose gradient, followed by discontinuous gradient centrifugation. The high isotope counts are found to associate with the fractions containing the virions.
  • a red fluorescent DSPE-PEG-rhodamine moiety can be incorporated into virions using the same types of micelles.
  • the MoMuLV is incubated with DSPE-PEG-rhodamine and then allowed to bind to murine or human cells.
  • the cells are next incubated with an anti-MoMuLV env antibody, followed by addition of a FITC-labeled secondary antibody (green fluorescence).
  • the resulting cells may be analyzed by FACS. It is found that a rhodamine signal, here used just as a tracer, is specifically detected on the murine cells containing viral receptors and that there is no non-specific signal detected on human cells which lack receptors for binding murine viruses.
  • a DSPE-PEG- ⁇ -MSH conjugate can be incubated with MoMuLV viral particles as described above, and assayed for the ability to bind to D10 human melanoma cells. Modified and non-modified MoMuLV particles are allowed to bind to the D10 cells, which then are tested for the presence of the Moloney env -specific FITC signal, using the methods described above. It is found that MoMuLV, which is a murine virus on its own unable to bind human cells, but once pre-treated with lipid-PEG- ⁇ -MSH conjugate can bind to human D10 cells.
  • Cell-entry elements aid in entrance of a TAGD vector into a host or target cell by providing membrane active components for the fusion between the TAGD vehicle and the target cell. Because a major limitation in efficiency in targeted drug delivery is crossing the membrane of the targeted cell, a TAGD vehicle with a functional cell-entry element is able to enter the target cell and deliver the therapeutic compound with improved efficiency.
  • the cell-entry element is a fusogenic moiety such as a peptide, that is, a peptide with membrane destabilizing abilities.
  • a fusogenic peptide induces formation of pores in the cell membrane by disruption of the ordered packing of the membrane phospholipids.
  • Some fusogenic peptides act to promote lipid disorder and in this way enhance the chance of merging or fusing of proximally positioned membranes of two membrane enveloped particles of various nature (e.g. cells, enveloped viruses, liposomes).
  • Other fusogenic peptides may simultaneously attach to two membranes, causing merging of the membranes and promoting their fusion into one.
  • fusogenic peptides include a fusion peptide from a viral envelope protein ectodomain, a membrane-destabilizing peptide of a viral envelope protein membrane-proximal domain from the cytoplasmic tails.
  • amphiphilic-region containing peptides include: melittin, magainins, the cytoplasmic tail of HIV1 gp41, microbial and reptilian cytotoxic peptides such as bomolitin 1, pardaxin, mastoparan, crabrolin, cecropin, entamoeba, and staphylococcal a-toxin; viral fusion peptides from (1) regions at the N terminus of the transmembrane (TM) domains of viral envelope proteins, e.g .
  • TM transmembrane
  • HIV-1, SIV, influenza, polio, rhinovirus, and coxsackie virus (2) regions internal to the TM ectodomain, e.g . semliki forest virus, Sindbis virus, rota virus, rubella virus and the fusion peptide from sperm protein PH-30 (3) regions membrane-proximal to the cytoplasmic side of viral envelope proteins e.g. in viruses of avian leukosis (ALV), Feline immunodeficiency (FIV), Rous Sarcoma (RSV), Moloney murine leukemia virus (MoMuLV), and spleen necrosis (SNV).
  • ABV avian leukosis
  • FMV Feline immunodeficiency
  • RSV Rous Sarcoma
  • MoMuLV Moloney murine leukemia virus
  • SNV spleen necrosis
  • fusogenic peptides have the propensity to form an amphiphilic alpha-helical structure when in the presence of a hydrophobic surface such as a membrane.
  • An amphiphilic peptide is a peptide in which one side is hydrophobic and the other side is hydrophilic.
  • the fusogenic peptide sequence is taken from a portion of a viral envelope protein which is 5' of the membrane spanning segment of the transmembrane portion of the envelope protein.
  • the subject amphiphilic fragment of interest is located after a hydrophobic region of the membrane-spanning segment of the transmembrane portion of the envelope protein which is often about 20 amino acids in length.
  • the fusogenic peptides of the present invention can be of various lengths.
  • the peptides include an amphiphilic amino acid sequence having from about 12 to about 35 amino acid residues.
  • the hydrophobic membrane-spanning segments often contains near their cytoplasmic end a glycine or a proline, generally associated with a turn structure.
  • the amphiphilicity of such membrane-proximal segments may be identified by the calculations of their hydrophobic moments. The examples of such membrane-proximal amphiphilic segments is shown in Appendix 2.
  • the fusogenic peptide comprises an amino acid sequence which is a derivative or analogue of the amino acid sequence hereinabove described.
  • the derivative or analogue has at least one substitution of an amino acid residue of the above-mentioned amino acid sequence.
  • the fusogenic peptide is comprised of an amino acid sequence derived from the cytoplasmic portion of the envelope protein as hereinabove described, and further includes at least a portion of the transmembrane protein.
  • fusogenic peptides derived from viruses are given in Table I below.
  • the negative numbers refer to amino acid residues in the C-terminal region of the predicted transmembrane region of the viral envelope protein
  • positive numbers refer to the number of residues from the cytoplasmic tail, beginning at the N-terminal, of the viral envelope that are in the peptide.
  • a peptide denoted as "-2/14" means that the isolated peptide includes (in an N-terminal to C-terminal direction), as the first two amino acid residues of the N- terminal, the two C-terminal amino acids of the predicted transmembrane portion and the last 14 amino acid residues are the 14 N-terminal amino acids of the predicted cytoplasmic tail.
  • Table I lists the positions of the most amphiphilic membrane-proximal segments in a number of viral envelope proteins.
  • ALV-avian leukosis virus BLV-bovine leukemia virus; EIA-equine infections anemia; FIV-feline immunodeficiency virus; HEP C-hepatits C; HIV-human immunodeficiency virus; HTLV-human T-cell leukemia virus; hRSV-human respiratory syncytial virus; infM2-influenza M2virus; INF-influenza; MMTV-Mouse Mammary Tumor Virus; MPMV-Mason Pfizer monkey virus; RSV-Rous Sarcoma Virus; PINF-parainfluenza; SNV-spleen necrosis virus; VSV-vesicular stomatitis virus; SimSrcV-HLB- simian sarcoma virus; MoMuLV-Moloney Murine Leukemia Virus.
  • the fusogenic peptide is the membrane-proximal cytoplasmic domain of the MoMuLV envelope protein (env). This domain has structural features conserved among a variety of viruses and contains a membrane-induced ⁇ -helix. This peptide is described in copending application Serial No. 09/112,544.
  • a copolymer of glutamic acid and leucine can be exploited as a fusogenic element.
  • These copolymers are powerful, conformational pH-dependent hydrophilic/hydrophobic carriers that can be used to deliver various substances into the cells. See WO 97/40854 .
  • the demonstrated membrane-penetrating and membrane-disturbing properties of these copolymers are, however, used for a different purpose in the context of the present invention. Rather than delivering substances into the cell this copolymer, being attached to the surface of a gene delivery particle surface, works as a pH-dependent fusogenic factor and/or as a multivalent and multifunctional carrier for other desired functions (fusogenic, immunoprotective, targeting functions etc.).
  • the fusogenic properties of the pH-dependent linker based on copolymers of glutamic acid with leucine or with other hydrophobic (natural or unnatural) amino acids, can be further augmented by use of the fusogenic peptides described supra.
  • One method for assembling the TAGD vector is via the use of micelle preparations containing the elements that are to be added to the vector.
  • the targeting ligand(s) and fusogenic element(s) can be covalently linked as described above to a linked polymer-lipid compound, and the resulting conjugated molecule then is used to prepare micelles.
  • Those micelles are added to a preparation of the core moiety whereby the conjugate is inserted into the surface of the core moiety.
  • Similar methods of "diffusive exchange" are described, for example in U.S. Patent No. 5,631,018 .
  • lipids of the viral envelope may be modified by using a preparation of lipids and/or immunoprotective polymers and a detergent such as sodium cholate to partially solubilize the envelope.
  • the detergent then is removed by exhaustive dialysis against phosphate-buffered saline (PBS), followed by insertion of fusogenic moieties and/or targeting moieties by partial micellation with sodium deoxycholate or other appropriate detergent. Detergent is then removed once again by exhaustive dialysis.
  • PBS phosphate-buffered saline
  • partial micellation refers to a viral membrane which is "softened” to allow incorporation of additional immunoprotective lipid or polymer components but that is not solubilized (micellized) to the point that the bilayer structure is lost.
  • the process of partial micellation can be controlled by monitoring the scattering of light of the vesicles using a laser light scattering instrument. Sufficient detergent is introduced into the vesicle dispersion to maintain the light scattering signal. Loss of the light scatter signal indicates true solubilization and loss of bilayer structure. After partial micellation, the integrity of the TAGD particles in one embodiment can be verified by determining the viral titer.
  • Useful detergents are well known to those skilled in the art and include, but are not limited to, bile salts (sodium cholate, deoxycholate, taurocholate, etc.), CHAPSO, octylglucoside, TRTTON-X derivatives, etc. These detergents can be zwitterionic such as CHAPSO, or nonionic such as octylglucoside or Triton-X. Non-ionic detergents are preferred, as they are less likely to cause loss of integrity in the TAGD particle. The selection of the detergent is determined taking into account the compatibility of a particular detergent with the surface protein to be inserted.
  • One additional method of assembling the TAGD vector in one embodiment is to covalently link one or more of the immunoprotective, targeting and cell entry elements to viral proteins present in the surface of the viral particle.
  • the element to be added can be prepared so as to carry an activated carboxyl group, which then may be reacted with free amino groups on the side chains of lysine molecules in the viral protein.
  • Other methods of linking molecules to proteins are well known in the art.
  • the side chains of surface lysine molecules can be reacted with 2-iminothiolane (Traut's reagent) to provide free sulfhydryl groups. Those groups can then be reacted with one or more of the immunoprotective, targeting and cell entry elements that carry maleimide groups.
  • Methods of preparing the TAGD vectors with the surface which contains novel functional elements include sonication or vortexing of an enveloped virus in the presence of addition lipids, whereby those additional lipids are introduced into the existing lipid membrane (see, for example, the methods described in Huang et al., Biochemistry. 8:344-52, (1969) ).
  • TAGD vectors that contain desired novel functional components may also be prepared by forming liposomes while in the presence of core containing particles. These methods include liposomes formation by detergent dialysis (see Kagawa et al. J. Biol. Chem. 246:5477-5487 (1971) ); freeze/thaw methods (see Mayer et al.
  • the TAGD core When the TAGD core is a retroviral vector, it may be produced in large quantity and purified by the methods described in U.S. Patent No. 5,661,022 .
  • the TAGD vectors will be by methods that are well known in the art.
  • the vectors are administered parenterally, more preferably intravenously or intraarterially
  • the vector may contain a reporter gene or a selective marker which can be used to track successful insertion and expression of the vector in a target cell.
  • the vector can be engineered to contain a reporter gene such as ⁇ -plactosidase ( ⁇ -gal), chloramphenicol acyl transferase (CAT), luciferase (luc), or green fluorescent protein (GFP).
  • CAT chloramphenicol acyl transferase
  • luc luciferase
  • GFP green fluorescent protein
  • the vector is then applied to a population of target cells and the level of the reporter gene product expression is measured. For control purposes this expression may be compared with the expression obtained with a vector that lacks either or both of the targeting ligand and the cell entry element. one or all of the immunoprotective elements.
  • the vector can contain a resistance marker, such as a neomycin resistance gene. Following application of the vector to the target cells, the cells are assayed for drug resistance.
  • in vitro efficacy of the vectors of the invention are well known in the art.
  • efficacy of the vector can be determined by study of the amelioration of one or more symptoms of the disease.
  • the in vivo efficacy can use measurement of defined clinical end points that are characteristic of the progress or extent of a disease.
  • Candidate diseases for gene therapy are well known in the art. See, for example, Verma et al., Nature 389:239 (1997 ) and reference cited therein.
  • a retroviral vector was functionally modified by non-genetic means to contain on its surface the ⁇ -MSH peptidomimetic ligand.
  • TAGD vectors targeted with this ligand are useful for the gene therapy of melanoma.
  • the experiments describe the encapsulation of retroviral particles.
  • Conjugation of carrier molecules was achieved by reaction of maleimidoyl derivatives with thiol groups present on the targting ligand.
  • PEG was conjugated to phosphatidylethanolamine using methods that are known in the art, and converted to a maleimido derivative (maleimidoyl-PEG-PE) using standard techniques.
  • the resulting compound was further conjugated to Cys 598-616 peptide (ILNRLVQFVKDRISVVQAL) as a targeting ligand peptide.
  • the conjugation was monitored using the property of the maleimidoyl group to absorb at 300 nm. (Hermanson, supra). Similar results were obtained for conjugation of lipid (i.e.
  • DSPE DSPE-PEG-SH with maleimidoylated analogs of ⁇ -MSH and other peptides, including ⁇ -MSH NLD , a peptidomimetic analog of MSH ([Nle4, D-Phe7]- ⁇ -MSH, obtained from NovaBiochem, San Diego,CA).
  • the level of the conversion of the peptides in conjugates was calculated based on molar absorbance of maleimidoyl group (630 M/cm -1 ). Completeness of the reaction is determined by measuring unbound thiol groups using Ellmann's reagent. Conjugates also were characterized by mass spectrometry (ES/MS and MALDI-TOF) to confirm that the conjugate contained no unbounded peptide that might interfere with the results of further experiments. Prepared conjugates were purified by gel-filtration in aprotic media and, in micellar form, by dialysis. See Karnoup et al., J. Peptide Res. 49:232-239 (1997) .
  • the resulting lipid-PEG- ⁇ -MSH conjugate was shown to retain biological activity by assay for melanin formation in melanoma B16 cells.
  • ⁇ -MSH, DSPE-PEG-SH, and DSPE-PEG- ⁇ -MSH conjugates were assayed at the same nanomolar concentrations.
  • the ⁇ -MSH conjugate induced melanin formation with comparable efficiency to the non-conjugated ⁇ -MSH peptide.
  • thermodynamically unstable micelles to fuse with larger membrane surfaces was exploited for the next step in the construction of the TAGD vehicle.
  • This method can be used to incorporate lipid-polymer-targeting ligand conjugates into the membrane surface of either liposomes (see Kirpotin, supra) or virions (see below).
  • the lipid-PEG- 125 I ⁇ -MSH conjugate was incubated with MoMuLV viral particles.
  • the modified virions were purified first by step sucrose gradient followed by discontinuous gradient centrifugation. The high isotope counts were shown to associate with the same fractions at which virions were pelleted.
  • DSPE-PEG-rhodamine red fluorescence
  • MoMuLV was incubated with DSPE-PEG-rhodamine and than allowed to bind to murine NIH 3T3 cells or human D10 melanoma cells. The cells were then incubated with anti-MoMuLV env antibody, followed by a FITC-labeled secondary antibody (green fluorescence). The resulting labeled cells (plus negative control cells) were analyzed by FACS.
  • a DSPE-PEG- ⁇ -MSH NLD conjugate was incubated with MoMuLV viral particles and assayed to demonstrate the ability of the conjugate to redirect the murine retroviral particle to bind D10 human melanoma cells.
  • the modified and non-modified MoMuLV particles were allowed to bind to the D10 cells and these cells were tested for the presence of the Moloney env -specific signal detected with anti-env primary nd FITC-labeled secondary antibodies (as described above).
  • the FACS profiles demonstrated a positive shift on the human D10 cells following binding of the MoMuLV pre-treated with lipid-PEG- ⁇ -MSH conjugate.
  • virions modified with lipid-PEG but lacking ⁇ -MSH did not exhibit similar binding to human cells.
  • murine retroviral particles can be modified to bind human melanoma cells by surface incorporation of an ⁇ -MSH peptidomimetic conjugate. Accordingly, it was shown that it is possible to redirect surface-modified particles to new specific host cells.
  • An alternative approach to create TAGD vehicles uses chemical conjugation of functional peptides, peptidomimetics and polymers, to the surface of virions directly or through a novel polyfunctional and polyvalent linker.
  • These chemical conjugation methods require the use of organic co-solvents and treatment with other reactive organic compounds and, thus, it first was necessary to establish working concentration of the chemical modifier reagents that sustain viral viability.
  • Viruses were subjected to the treatment with a variety of organic solvents and conjugates. It was found that MoMuLV is surprisingly stable to treatment with organic solvents, retaining almost full infectivity after 30min treatment with up to 5 % (v/v) acetonitrile or DMF. These results indicate that the virus is able to withstand the conditions necessary to carry out chemical modifications of the virions.
  • the reaction product was precipitated with ether, washed with ether and pentane, and dried.
  • the resulting activated linker (10 mg) was dissolved in 2 ml DMF.
  • the peptide ( ⁇ -MSH NLD , 1 mg) was added, followed by 25 ⁇ l DIPEA.
  • the reaction was shaken overnight at room temperature, and then stored at -20°C. Addition of the linker in this fashion ensured that some of the active pentafluorophenyl esters were still retained for further conjugations to the surface of the gene delivery vehicle.
  • This linker-MSH conjugate then was incubated with the viral particle under similar conditions to those described above for DSPE-PEG-MSH. After modification, the MoMuLV particles were assayed for incorporation of ⁇ -MSH into the viral particle using Western blot analysis. The ⁇ -MSH positive signal was found to be associated with the env protein of the modified virus, but was not present on non-modified viruses to which non-conjugated ⁇ -MSH was added in a negative control. Addition of the MSH ligand in this fashion also successfully redirected the binding specificity of the modified MoMuLV particle.
  • UV inactivated Sendai virus was used to provide such a functional retargeting and fusogenic enveloping surface to deliver the genetic content of MoMuLV particle to a novel host.
  • Sendai virus previously has been demonstrated to fuse with bare membrane surfaces, and has been applied as a component of fusogenic liposomes in gene delivery (reviewed in Nakanishi et al.; Journal of Controlled Release 54:61-68 (1998) ).
  • UV-inactivated Sendai virus was used to fuse with MoMuLV encoding a green fluorescent protein (GFP) marker gene.
  • GFP green fluorescent protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (9)

  1. Nicht in der Natur auftretender Gentherapie-Vektor für die zellspezifische Abgabe einer Nucleinsäure an eine Zielzelle,
    umfassend einen rekombinanten viralen Kern und eine nicht in der Natur auftretende funktionelle Oberflächeneinheit,
    wobei der Kern ein Nucleinsäuremolekül umfasst,
    wobei mindestens ein Expressionsprodukt dieses Vektors eine therapeutische Nucleinsäure, Peptid oder Protein ist; und
    wobei die funktionelle Oberflächeneinheit folgendes umfasst:
    ein Immunoschutzelement, bei dem es sich um eine synthetische polymere Einheit handelt, die ein Copolymeres von Glutaminsäure mit Leucin umfasst,
    ein Zellzugangselement mit einer Membran-destabilisierenden Einheit, die eine amphiphile α-Helix umfasst, und
    ein abzielendes Element, bei dem es sich um einen Peptidliganden für einen Zelloberflächenrezeptor handelt,
    wobei das Vehikel zur spezifischen Bindung an eine Zielzelle und zur Abgabe des Kerns an die Zielzelle befähigt ist.
  2. Vektor nach Anspruch 1, wobei der virale Kern ferner mindestens ein virales Capsid-Protein umfasst.
  3. Vektor nach Anspruch 1, wobei Polyethylenglycol mit dem viralen Kern über einen Linker, der ein Copolymeres von Glutaminsäure mit Leucin umfasst, verknüpft ist.
  4. Vektor nach Anspruch 1, wobei das abzielende Peptid an einen Rezeptor bindet, der in den zur Diskussion stehenden Zellen stärker exprimiert wird als in normalen Zellen.
  5. Vektor nach Anspruch 1, wobei es sich bei der abzielenden Einheit um ein RGD-Peptid handelt.
  6. Vektor nach Anspruch 1, wobei sich die amphiphile α-Helix von der C-terminalen Domäne eines viralen env-Proteins ableitet.
  7. Vektor nach Anspruch 6, wobei es sich bei der C-terminalen Domäne um die C-terminale Domäne des Moloney-Leukämie-Virus-env-Proteins handelt.
  8. Vektor nach Anspruch 7, wobei die C-terminale Domäne die Aminosäuren 598-616 des Moloney-Leukämie-Virus-env-Proteins umfasst.
  9. Vektor nach Anspruch 1 zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung einer genetischen Krankheit, wobei es sich beim Expressionsprodukt um ein Produkt handelt, das bei der Behandlung dieser Krankheit wirksam ist.
EP00957535A 1999-08-19 2000-08-18 Gezielte verabreichung von kuenstlichen genen Expired - Lifetime EP1204761B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US377153 1999-08-19
US09/377,153 US20020064520A1 (en) 1999-08-19 1999-08-19 Targeted artificial gene delivery
PCT/US2000/022619 WO2001012235A2 (en) 1999-08-19 2000-08-18 Targeted artificial gene delivery

Publications (2)

Publication Number Publication Date
EP1204761A2 EP1204761A2 (de) 2002-05-15
EP1204761B1 true EP1204761B1 (de) 2008-04-02

Family

ID=23487987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00957535A Expired - Lifetime EP1204761B1 (de) 1999-08-19 2000-08-18 Gezielte verabreichung von kuenstlichen genen

Country Status (10)

Country Link
US (2) US20020064520A1 (de)
EP (1) EP1204761B1 (de)
JP (1) JP2003507348A (de)
CN (1) CN1237179C (de)
AT (1) ATE391186T1 (de)
AU (1) AU6913800A (de)
CA (1) CA2380517A1 (de)
DE (1) DE60038494D1 (de)
NZ (1) NZ517241A (de)
WO (1) WO2001012235A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US8865188B2 (en) 2011-09-09 2014-10-21 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
US9017695B2 (en) 2009-04-14 2015-04-28 Biomed Realty, L.P. Chimeric therapeutics, compositions, and methods for using same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017511A1 (fr) * 1999-09-03 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Procede de liberation intracellulaire prolongee de medicaments et de preparations
CA2404737C (en) * 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
US7589059B2 (en) * 2002-07-26 2009-09-15 Roche Madison Inc. Delivery of molecules and complexes to mammalian cells in vivo
ATE506445T1 (de) * 2003-02-17 2011-05-15 Fuso Pharmaceutical Ind Neuartiger virusvektor
EP1559790A1 (de) * 2004-02-02 2005-08-03 International University Bremen Gmbh Vesikel zum Abtrennen von Substanzen aus flüssigen Medien
ATE460922T1 (de) * 2006-04-07 2010-04-15 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
EP3494974B1 (de) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metall-bisphosphonat-nanopartikel zur krebstherapie sowie bildgebung und zur behandlung von knochenerkrankungen
JP7090034B2 (ja) * 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
EP0966303A2 (de) * 1996-05-01 1999-12-29 Antivirals Inc. Polypeptidkonjugate zum transport von substanzen durch zellmembranen
AU745056B2 (en) * 1997-04-03 2002-03-07 Genzyme Corporation Polymer-modified viruses
ES2303726T3 (es) * 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
CA2333855A1 (en) * 1998-07-09 2000-01-20 University Of Southern California Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US9017695B2 (en) 2009-04-14 2015-04-28 Biomed Realty, L.P. Chimeric therapeutics, compositions, and methods for using same
US8865188B2 (en) 2011-09-09 2014-10-21 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins

Also Published As

Publication number Publication date
US20080103108A1 (en) 2008-05-01
EP1204761A2 (de) 2002-05-15
ATE391186T1 (de) 2008-04-15
WO2001012235A2 (en) 2001-02-22
WO2001012235A3 (en) 2001-05-25
JP2003507348A (ja) 2003-02-25
DE60038494D1 (de) 2008-05-15
CA2380517A1 (en) 2001-02-22
NZ517241A (en) 2004-01-30
CN1420934A (zh) 2003-05-28
AU6913800A (en) 2001-03-13
US20020064520A1 (en) 2002-05-30
CN1237179C (zh) 2006-01-18

Similar Documents

Publication Publication Date Title
US20080103108A1 (en) Targeted artificial gene delivery
Pei et al. Overcoming endosomal entrapment in drug delivery
Durymanov et al. Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers
US5766902A (en) Transfection process
Pichon et al. Histidine-rich peptides and polymers for nucleic acids delivery
Amiji Polymeric gene delivery: principles and applications
US6224903B1 (en) Polymer-lipid conjugate for fusion of target membranes
US7037520B2 (en) Reversible masking of liposomal complexes for targeted delivery
US20150272885A1 (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US20030203865A1 (en) Lipid-comprising drug delivery complexes and methods for their production
Fernandez et al. Engineered nanoscaled polyplex gene delivery systems
WO1997000965A2 (en) A lipidic vector for nucleic acid delivery
US20050163832A1 (en) Intracellular delivery of therapeutic agents
JP2002502243A (ja) トランスフェクション活性を有するインテグリン−ターゲッティングベクター
Lieser et al. Incorporation of endosomolytic peptides with varying disruption mechanisms into EGFR-Targeted protein conjugates: the effect on intracellular protein delivery and EGFR specificity in breast cancer cells
US20010044147A1 (en) Delivery vehicles comprising stable lipid/nucleic acid complexes
Chen et al. Overcoming biological barriers by virus-like drug particles for drug delivery
J. Glover Artificial viruses: exploiting viral trafficking for therapeutics
Herringson et al. Targeting of plasmid DNA‐lipoplexes to cells with molecules anchored via a metal chelator lipid
AU2005202079A1 (en) Targeted artificial gene delivery
US20120258540A1 (en) Methods for modifying virus surfaces
RU2537262C2 (ru) Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк
CA2375854A1 (en) Novel liposomal vector complexes and their use in gene therapy
Subramanian Rate limiting steps in nonviral gene transfer and the design of nuclear targeting scaffolds for the improved transfection of endothelium
Pedro Molecular Determinants of Virus-Like Nanoparticle Assembly in vitro and in Animal Cell Culture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020207

17Q First examination report despatched

Effective date: 20031223

17Q First examination report despatched

Effective date: 20031223

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROZENBERG, YANINA

Inventor name: MEDVEDKIN, VIACHESLAV

Inventor name: ANDERSON, W., FRENCH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60038494

Country of ref document: DE

Date of ref document: 20080515

Kind code of ref document: P

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080902

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080702

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

26N No opposition filed

Effective date: 20090106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090123